GleamWall
中文EN

ARVN ARVINAS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%

Returns

ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$262.60M$263.40M
R&D expense$285.20M$348.20M
SG&A expense$95.90M$165.40M
Operating income-$118.50M-$250.20M
Interest expense—$0
Pretax income-$80.50M-$198.30M
Income tax$300,000$600,000
Net income-$80.80M-$198.90M
EBITDA-$115.50M-$245.60M
EPS (basic)-1.14-2.77
EPS (diluted)-1.14-2.77
Weighted avg. shares (diluted)70.90M71.90M
Balance sheet
Cash & equivalents$142.90M$100.50M
Short-term investments$542.50M$938.90M
Receivables$1.00M$5.70M
Current assets$700.70M$1.07B
PP&E, net$5.20M$7.00M
Total assets$717.90M$1.09B
Current liabilities$142.50M$229.80M
Short-term debt$200,000$200,000
Long-term debt$400,000$600,000
Total debt$600,000$800,000
Total liabilities$284.00M$529.70M
Shareholders' equity$433.90M$561.70M
Net debt-$142.30M-$99.70M
Shares outstanding63.50M68.80M
Cash flow statement
Operating cash flow-$273.80M-$259.30M
Capital expenditure$1.90M$1.80M
Free cash flow-$275.70M-$261.10M
Investing cash flow$407.60M$34.70M
Financing cash flow-$91.40M$7.90M
Depreciation & amortization$3.00M$4.60M
Stock-based compensation$44.00M$88.20M
Share buybacks$91.90M$0

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.